Results 71 to 80 of about 540,096 (367)

E2A selectively regulates TGF‐β–induced apoptosis in KRAS‐mutant non‐small cell lung cancer

Molecular Oncology, EarlyView.
Ability to induce apoptosis by TGF‐β is frequently lost in advanced lung adenocarcinoma despite intact TGF‐β signaling. We identify E2A as a mutant KRAS–dependent mediator of resistance to TGF‐β–induced apoptosis. TGF‐β induces E2A via SMAD3 in mutant KRAS cells, and E2A silencing restores apoptosis and enhances radiation response in cell lines ...
Sergei Chuikov, Shiva Krishna Katkam, Zhefan Wang, Venkateshwar G. Keshamouni   +3 more
wiley   +1 more source

Meta-analysis of comparing part-solid and pure-solid tumors in patients with clinical stage IA non-small-cell lung cancer in the eighth edition TNM classification

, 2019
Tian Jiang, Ming Li, Miao Lin, Mengnan Zhao, Cheng Zhan, Mingxiang FengDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, People’s Republic of ChinaObjective: The aim of the study was to compare the prognoses ...
Zhao M, Feng M, Zhan C, Jiang T, Li M, Lin M   +5 more
core  

Ovary: Epithelial tumors [PDF]

, 2003
Review on Ovary: Epithelial tumors, with data on clinics, and the genes ...
L Lee-Jones, Lee-Jones, L, Lee-Jones, Lisa   +2 more
core   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Potential of epigenetic therapies in the management of solid tumors

, 2015
Victor Valdespino,1 Patricia M Valdespino2 1Health Attention Department, Universidad Autónoma Metropolitana, Mexico; 2Bacterial Ecology and Epigenetics Laboratory, Universidad Nacional Autónoma de México, Mexico Abstract: Cancer is
Valdespino V, Valdespino PM
core  

Cell Plasticity-Related Phenotypes and Taxanes Resistance in Castration-Resistant Prostate Cancer

Frontiers in Oncology, 2020
The prostatic tumor cells plasticity is involved in resistance to hormone-therapy, allowing these cells to survive despite androgen receptor inhibition. However, its role in taxanes resistance has not been fully established. Gene expression of plasticity-
Natalia Jiménez, Natalia Jiménez, Òscar Reig, Òscar Reig, Òscar Reig, Ruth Montalbo, Ruth Montalbo, Maria Milà-Guasch, Lluis Nadal-Dieste, Lluis Nadal-Dieste, Giancarlo Castellano, Juan José Lozano, Iván Victoria, Iván Victoria, Iván Victoria, Albert Font, Alejo Rodriguez-Vida, Joan Carles, Cristina Suárez, Montserrat Domènech, Núria Sala-González, Pedro Luis Fernández, Leonardo Rodríguez-Carunchio, Sherley Díaz, Aleix Prat, Aleix Prat, Aleix Prat, Aleix Prat, Mercedes Marín-Aguilera, Mercedes Marín-Aguilera, Mercedes Marín-Aguilera, Begoña Mellado, Begoña Mellado, Begoña Mellado, Begoña Mellado   +34 more
doaj   +1 more source

Correction: High-dose thiotepa, in conjunction with melphalan, followed by autologous hematopoietic stem cell transplantation in patients with pediatric solid tumors, including brain tumors [PDF]

, 2022
Junichi Hara, Kimikazu Matsumoto, Naoko Maeda, Mariko Takahara‐Matsubara, Saori Sugimoto, Hiroaki Goto   +5 more
openalex   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Albumin-bound paclitaxel in solid tumors: clinical development and future directions

, 2015
Madappa N Kundranda,1 Jiaxin Niu21Medical Oncology, Banner MD Anderson Cancer Center, Gilbert, 2Department of Medical Oncology, Cancer Treatment Centers of America, Goodyear, Arizona, USA Abstract: Albumin-bound paclitaxel (nab-paclitaxel) is a solvent ...
Kundranda MN, Niu J
core  

Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation

Molecular Cancer
Background The identification of novel therapeutic strategies to overcome resistance to the MEK inhibitor trametinib in mutant KRAS lung adenocarcinoma (LUAD) is a challenge.
Ander Puyalto, María Rodríguez-Remírez, Inés López, Irati Macaya, Elizabeth Guruceaga, María Olmedo, Anna Vilalta-Lacarra, Connor Welch, Sergio Sandiego, Silvestre Vicent, Karmele Valencia, Alfonso Calvo, Ruben Pio, Luis E. Raez, Christian Rolfo, Daniel Ajona, Ignacio Gil-Bazo   +16 more
doaj   +1 more source